<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04576039</url>
  </required_header>
  <id_info>
    <org_study_id>PAEC</org_study_id>
    <nct_id>NCT04576039</nct_id>
  </id_info>
  <brief_title>Ultrasonographic Appearance of the Endometrium After Ulipristalacetate Use and Endometrial Changes</brief_title>
  <official_title>Ultrasonographic Appearance of the Endometrium After Saline Infusion in Women Presenting With a Thickened Endometrium After the Use of Ulipristalacetate.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      If endometrial thickening is visualised (&gt;10mm) after the use of ulipristalacetate in case of&#xD;
      medical treatment for uterine fibroids a saline infusion and sonographic examination will be&#xD;
      performed to evaluate the endometrium and exclude intra-uterine pathology.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When ultrasonographic examination during follow up of a treatment with ulipristalacetate&#xD;
      shows a thickening of the endometrium of 10mm or more ( thickening described in 10% of&#xD;
      ulipristalacetate users and is completely benign), a saline infusion can help to exclude&#xD;
      pathology in the uterine cavity. Saline infusion helps to better delineate the uterine cavity&#xD;
      and endometrium. If fibroids or polyps are present in the uterine cavity they will clearly be&#xD;
      seen.&#xD;
&#xD;
      This study was set up to describe how the endometrial changes after Esmya use appear on&#xD;
      saline infusion sonography. This study can help to recognize ultrasonographic images in women&#xD;
      presenting with thickened endometrium after Ulipristalacetate use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ultrasonographic morphology of the endometrium at saline infusion sonography</measure>
    <time_frame>1 week</time_frame>
    <description>thickness and appearance of the endometrium</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>diagnostic ability to exclude intrauterine pathology</measure>
    <time_frame>1week</time_frame>
    <description>presence yes or no of intra uterine pathology as polyps or fibroids</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Uterine Fibroid</condition>
  <condition>Endometrial Cyst</condition>
  <arm_group>
    <arm_group_label>presenting with thickened endometruim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>women presenting with thickened endometrium after the use of ulipristalacetate will undergo a saline infusion in the uterus and immediate ultrasonographic control to visualise the morphology of the endometrium.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>saline infusion sonography</intervention_name>
    <description>Instillation of 10cc of saline infusion in the uterine cavity while performing an ultrasonic evaluation of the uterine cavity and endometrium.</description>
    <arm_group_label>presenting with thickened endometruim</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with thickened endometrium on ultrasound (defined as double endometrium&#xD;
             thickness of â‰¥10mm) at the end of their treatment with ulipristalacetate.&#xD;
&#xD;
          -  Normal double endometrium thickness before the use of ESMYA (&lt;10mm)&#xD;
&#xD;
          -  BMI &gt;18 - &lt; 30&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known type 0 or 1 fibroids&#xD;
&#xD;
          -  Known intrauterine pathology&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Degreef, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis UZBrussel</name>
      <address>
        <city>Jette</city>
        <state>Brussels</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Stefan Cosyns</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

